SCHEMBL24620633

SCHEMBL24620633

CN1CCN(C2CCN(c3ccc(Nc4ncc(C(F)(F)F)c(Nc5cccc6c5C(=O)NC6)n4)c(OC(F)F)c3)CC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 17/20 0.56
▸ INSR P06213 12/20 0.53
▸ IGF1R P08069 11/20 0.53
▸ FGFR1 P11362 3/20 0.53
▸ FGFR2 P21802 3/20 0.53
▸ FGFR4 P22455 3/20 0.53
▸ FGFR3 P22607 3/20 0.53
▸ PLK1 P53350 3/20 0.53
▸ EGFR P00533 4/20 0.50
▸ CHEK1 O14757 2/20 0.50
▸ AURKA O14965 2/20 0.50
▸ NUAK1 O60285 2/20 0.50
▸ JAK2 O60674 2/20 0.50
▸ STK10 O94804 2/20 0.50
▸ PRKD3 O94806 2/20 0.50
▸ CHEK2 O96017 2/20 0.50
▸ ABL1 P00519 2/20 0.50
▸ ERBB2 P04626 2/20 0.50
▸ LCK P06239 2/20 0.50
▸ FYN P06241 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30833015 1.00 ALK (0.56) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL29791431 0.97 ALK (0.54) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL24620213 0.97 ALK (0.54) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL29791543 0.94 ALK (0.54) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL24620237 0.94 ALK (0.54) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL27175302 0.94 ALK (0.54) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL29791375 0.94 ALK (0.54) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL24620572 0.94 ALK (0.54) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL29791402 0.94 ALK (0.54) ALKINSRIGF1RFGFR1FGFR2
SCHEMBL24620475 0.94 ALK (0.55) ALKPLK1EGFRULK1MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092763-A1 ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-03-21 — — US claimed
US-20240092763-A1 ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-03-21 — — US disclosed
WO-2022147622-A1 ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092763-A1 ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF NUAK1, NUAK2, NEK1 ALK 430/4885INSR 1031/4885IGF1R 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback